

Supplementary Table 6. Summary of all the available 33 protein sequences from the stop-gain and frameshift mutations and their involved isoforms

No.	Mutation	Phenotype	Impacted isoforms [†]	Reference
1	p.R85X [§]	CA plus [‡]	1, 4, 5, 6, 7, 10	Cheng et al. (2021) [§]
2	p.G185R [§]	CA plus [‡]	1, 4, 5, 6, 7, 10	Izumi et al. (2013) [†]
3	p.N641Mfs*20 [§]	Pure CA	1, 4, 5, 6, 7, 10	Our study
4	p.K1094X [§]	CA plus* [‡]	1, 4, 5, 6, 7, 10	Cheng et al. (2021) [§]
5	p.Q1295X [§]	Pure CA	1, 4, 5, 6, 7, 10	Our study
6	p.Q1498Rfs*3 [§]	CA plus [‡]	1, 4, 6, 7, 10	Duan et al. (2021) [‡]
7	p.Q1741X [§]	Pure CA [‡]	1, 4, 7, 10	Kim et al. (2019) [§]
8	p.Q2282Sfs*3	Pure CA	1, 4, 7, 10	Yoshinaga et al. (2017) [‡]
9	p.S2526Sfs*8	CA plus* [‡]	1, 4, 7, 10	Qian et al. (2022) [§]
10	p.I2995V [§]	Pure CA	1, 4, 7, 10, 12	Kim et al. (2019) [§]
11	p.E3053fs	Pure CA	1, 4, 7, 12	Cheng et al. (2021) [§]
12	p.R3479X [§]	CA plus [‡]	1, 4, 7	Cheng et al. (2021) [§]
13	p.R3597X	Pure CA	1, 4, 7	Izumi et al. (2013) [†]
14	p.L4224Pfs*16	Pure CA	1, 4, 7	Duan et al. (2021) [‡]
15	p.D4368Tfs*2 [§]	Pure CA	1, 4, 7	Duan et al. (2021) [‡]
16	p.Y4534fs4539X	Pure CA	1, 4, 7	Izumi et al. (2013) [†]
17	p.E5112D [§]	Pure CA	1, 4, 7	Kim et al. (2019) [§]
18	p.E5273fs [§]	CA plus* [‡]	1, 4, 7	Cheng et al. (2021) [§]
19	p.H5844fs [§]	CA plus	1, 2, 4, 8	Cheng et al. (2021) [§]
20	p.Arg5982Ter [§]	CA plus	1, 2, 4, 8	Peng et al. (2018) [§]
21	p.R6156L [§]	Pure CA [‡]	1, 2, 4, 8	Duan et al. (2021) [‡]
22	p.Trp6228Ter [§]	CA plus	1, 2, 4, 8	Peng et al. (2018) [§]
23	p.R6380*	CA plus	1, 2, 4, 8	Kume et al. (2019) [§]
24	p.L6946fs [§]	CA plus [‡]	1, 2, 4, 8	Cheng et al. (2021) [§]
25	p.Arg7155* [§]	CA plus	1, 2, 4, 8	Naruse et al. (2021) [‡]
26	p.Arg7190Ter	CA plus	1, 2, 4, 8	Peng et al. (2018) [§]
27	p.Q7319* [§]	CA plus	1, 2, 4, 8	Duan et al. (2021) [‡]
28	p.R7486fs7488X [§]	CA plus	1, 2, 4, 8	Izumi et al. (2013) [†]
29	p.Lys7612Serfs*28 [§]	CA plus	1, 2, 4, 8	Naruse et al. (2021) [‡]
30	p.L7747Afs*28	CA plus	1, 2, 4, 8, 11	Duan et al. (2021) [‡]
31	p.V7875Afs*47 [§]	CA plus	1, 2, 3, 4, 8, 9, 11	Duan et al. (2021) [‡]
32	p.T7926K [§]	CA plus	1, 2, 3, 4, 8, 9, 11	Duan et al. (2021) [‡]
33	p.R8652* [§]	CA plus [‡]	1, 2, 3, 4, 8, 9, 11	Duan et al. (2021) [‡]

The number order of these mutations are arranged according to their position from the N-terminus to the C-terminus. *the patients harbor no mutation involving in those isoforms near the C-terminus, but they exhibit ataxia plus syndromes; [‡]the patients harbor another mutation involving in those isoforms near the C-terminus; [†]the patients harbor another splice site mutation; [§]heterozygous mutations or co-existing mutations on the same patient; [‡]the patients harbor a mutation involving in those isoforms near the C-terminus, but they exhibit pure cerebellar ataxia; [†]the names of nesprin-1 isoforms are based on UniProt ID: Q8NF91 (<https://www.uniprot.org/>, accessed on September 17, 2022). The synonyms of these isoforms: 1, Nesprin-1 Giant or Enaptin; 2, Nesprin-1 beta; 3, Nesprin-1 alpha; 4, Nesprin-1 isoform 4; 5, Nesprin-1 isoform 5; 6, Nesprin-1 isoform 6; 7, Nesprin-1 isoform 7; 8, Nesprin-1 beta 2; 9, Nesprin-1 alpha 2; 10, Drop 1; 11, Myne-1; 12, GSRP-56. Pure CA, pure cerebellar ataxia; CA plus, ataxia plus syndromes.